ARCHIVE

• JPMA Approves Plans to Strengthen Activities of Its Thinktank
  March 31, 2003

• March 31, 2003

• Tanabe Licenses Transmucosal Oral Fentanyl from Cephalon
  March 31, 2003

• Predicting Disease Prevalence to Be Major Issue: JPMA Seminar
  March 31, 2003

• GL for Treatment of H. pylori Infection Revised
  March 31, 2003

• 1 in 3 GPs Rarely See MRs: Survey
  March 31, 2003

• AstraZeneca to Study Proper Use of Iressa with IMSUT
  March 31, 2003

• MR Activities Over-concentrated in GP market: MOSS Institute Survey
  March 31, 2003

• Promoting Development of Venture Biz Stressed: Regenerative Medicine Seminar
  March 31, 2003

• Reed Exhibitions Japan to Hold Bio Partnering Forum in May
  March 31, 2003

• Methods of Drug Risk/Benefit Assessment Studied by RAD-AR Council Japan
  March 31, 2003

• BUSINESS NEWS IN BRIEF
  March 31, 2003

• RESEARCH & DEVELOPMENT NEWS IN BRIEF
  March 31, 2003

• Chuikyo Agrees on Need to Separate Materials from Skills in Med Fee Evaluation
  March 31, 2003

• JACDS Submits OTC Sales Deregulation Proposal to Korosho
  March 31, 2003

• Generic Houses to Be Required to Conduct the Same PMS as Original Makers
  March 31, 2003

• JPA, AJDA, NMRA Oppose OTC Drug Sales by General Retailers
  March 31, 2003

• 989 Bio-derived Products Recommended for Designation
  March 31, 2003

• OTC NEWS IN BRIEF
  March 31, 2003

• Trend Toward For-profit Participation in Healthcare "Will Not Stop": Mr Konoike
  March 31, 2003

ページ

• « 先頭
• ‹ Prev
• …
• 608
• 609
• 610
• 611
• 612
• 613
• 614
• 615
• 616
• …
• Next ›
• 最終 »